R Squared Ltd Purchases New Stake in Pulmonx Corporation $LUNG

R Squared Ltd purchased a new stake in shares of Pulmonx Corporation (NASDAQ:LUNG) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 16,011 shares of the company’s stock, valued at approximately $41,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its position in Pulmonx by 1.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company’s stock valued at $2,160,000 after buying an additional 5,414 shares during the period. Vontobel Holding Ltd. bought a new position in Pulmonx during the first quarter valued at about $82,000. PDT Partners LLC grew its position in Pulmonx by 45.1% during the first quarter. PDT Partners LLC now owns 71,637 shares of the company’s stock valued at $482,000 after buying an additional 22,259 shares during the period. Deutsche Bank AG grew its position in Pulmonx by 4.2% during the first quarter. Deutsche Bank AG now owns 1,147,105 shares of the company’s stock valued at $7,720,000 after buying an additional 46,116 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Pulmonx by 97.3% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,610 shares of the company’s stock valued at $1,115,000 after buying an additional 81,669 shares during the period. Institutional investors own 91.04% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on LUNG. Stifel Nicolaus reduced their price target on shares of Pulmonx from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Wells Fargo & Company cut their target price on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. Lake Street Capital cut their target price on shares of Pulmonx from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. D. Boral Capital reiterated a “buy” rating and set a $16.00 target price on shares of Pulmonx in a research report on Monday, September 8th. Finally, Wall Street Zen lowered shares of Pulmonx from a “hold” rating to a “sell” rating in a research report on Friday, October 3rd. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $7.66.

Pulmonx Trading Up 3.1%

Shares of Pulmonx stock opened at $1.64 on Monday. Pulmonx Corporation has a 12-month low of $1.47 and a 12-month high of $9.37. The company has a market cap of $66.83 million, a price-to-earnings ratio of -1.15 and a beta of 0.42. The company has a current ratio of 5.35, a quick ratio of 4.63 and a debt-to-equity ratio of 0.54. The company’s 50-day moving average price is $1.67 and its 200-day moving average price is $2.68.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. The firm had revenue of $23.86 million for the quarter, compared to the consensus estimate of $23.46 million. Pulmonx has set its FY 2025 guidance at EPS. On average, equities analysts expect that Pulmonx Corporation will post -1.55 earnings per share for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.